Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

14.15USD
2 Dec 2016
Change (% chg)

$0.35 (+2.54%)
Prev Close
$13.80
Open
$13.90
Day's High
$14.60
Day's Low
$13.65
Volume
166,794
Avg. Vol
193,933
52-wk High
$17.91
52-wk Low
$7.86

MNTA.OQ

Chart for MNTA.OQ

About

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $1,031.59
Shares Outstanding(Mil.): 71.02
Dividend: --
Yield (%): --

Financials

  MNTA.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.34 -- --
ROI: -23.85 -1.09 14.95
ROE: -25.51 -2.39 16.29

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

UPDATE 1-Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

BRIEF-Momenta Pharmaceuticals says positive top-line phase 3 results for M923, a proposed Humira biosimilar

* Momenta Pharmaceuticals announces positive top-line phase 3 results for M923, a proposed Humira (adalimumab) biosimilar

Nov 29 2016

Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech company Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

BRIEF-Momenta Pharmaceuticals names Scott Storer as CFO

* Says Storer is expected to begin at Momenta on november 28, 2016 and will replace Momenta's current CFO Rick Shea

Nov 02 2016

BRIEF-Momenta and Mylan initiate early-stage study for proposed biosimilar of Orencia

* Mylan nv - momenta has achieved milestone necessary to earn a $25 million payment from mylan.

Nov 02 2016

BRIEF-Mmenta Pharmaceuticals to regain global development and commercialization rights to M923

* Momenta Pharmaceuticals to regain global development and commercialization rights to M923, a proposed biosimilar of HUMIRA (adalimumab), through termination of collaboration agreement with Baxalta, now part of Shire

Sep 27 2016

BRIEF-Momenta Pharmaceuticals reports Q2 loss per share $0.31

* Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S

Aug 04 2016

BRIEF-Momenta Pharmaceuticals appoints Steven Gilman to board of directors

* Momenta pharmaceuticals appoints steven c. Gilman, ph.d. To board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 23 2016

Momenta, Sandoz allowed to broaden claims over quality test patent

A federal judge has allowed Momenta Pharmaceuticals and Sandoz Inc to broaden a lawsuit accusing Amphastar Pharmaceuticals of infringing a patent on quality control methods used in making the blood thinner enoxaparin, the generic form of French drug maker Sanofi's Lovenox.

Jun 23 2016

Competitors

Earnings vs. Estimates